Compare TransMedics Group Inc (TMDX) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Visa Inc — how do they compare? TransMedics Group Inc trades at $80.9 (market cap $2.74B), while Visa Inc trades at $380.4 (market cap $704.20B). The key difference: Visa Inc is far larger — about 257× TransMedics Group Inc's market cap, and Visa Inc pays a 0.71% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Visa Inc for 115 Days on average.
| TMDX | V | |
|---|---|---|
Market Cap | $2.74B | $704.20B |
Volume | 949,331 | 6,405,857 |
Sector | Health | Financials |
52-Week High | $150.42 | $384.14 |
52-Week Low | $61.99 | $295.52 |
Typical Hold Time | 24 Days | 115 Days |
Enterprise Value | $3.13B | $714.78B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Visa (V) trades at $372.10, up 0.39% with strong bullish technical momentum. The company demonstrates robust fundamentals with 2025 revenue of $40B and net income margin of 50.78%. Recent earnings beats and a consensus price target of $422.24 reflect Wall Street optimism. Visa's expansion into AI-powered commerce through Intelligent Commerce Connect positions it for future growth while maintaining exceptional profitability metrics including 61.79% ROE.
Visa presents a compelling investment case with consistent earnings outperformance and dominant market position. Key opportunities include AI integration and stablecoin partnerships, while risks involve regulatory scrutiny and fintech competition. With 85% analyst buy ratings and 13% upside to consensus target, the stock offers growth potential despite premium valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
